Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.

The Journal of clinical investigation - 1 Apr 2020

Hu Kewen, Li Kun, Lv Jing, Feng Jie, Chen Jing, Wu Haigang, Cheng Feixiong, Jiang Wenhao, Wang Jieqiong, Pei Haixiang, Chiao Paul J, Cai Zhenyu, Chen Yihua, Liu Mingyao, Pang Xiufeng

Abstract excerpt

Oncogenic KRAS is a major driver in lung adenocarcinoma (LUAD) that has yet to be therapeutically conquered. Here we report that the SLC7A11/glutathione axis displays metabolic synthetic lethality with oncogenic KRAS. Through metabolomics approaches, we found that mutationally activated KRAS strikingly increased intracellular cystine levels and glutathione biosynthesis. SLC7A11, a cystine/glutamate antiporter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoplasmic Reticulum Stress

Share to Glutathione

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31874110
DOI: 10.1172/JCI124049
PMCID: PMC7108883

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.PMID 31874110Read ↗

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapySemantic proximity Read ↗

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.Semantic proximity Read ↗

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Semantic proximity Read ↗

LAPTM4B counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of SLC7A11 in non-small cell lung cancerSemantic proximity Read ↗

Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancerSemantic proximity Read ↗

Patient-Specific Pharmacogenomics unveils xCT as a Key Regulator for Druggable Metabolic and Proliferation Pathways in Colon CancerSemantic proximity Read ↗

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.Semantic proximity Read ↗

Low tumor glutathione level as a sensitivity marker for glutamate‑cysteine ligase inhibitorsSemantic proximity Read ↗

Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapySemantic proximity Read ↗

The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.Semantic proximity Read ↗

Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells.Semantic proximity Read ↗

Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomographySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.